Abstract library

148 results for "carcinoids".
#2174 Clinicopathologic Features and Treatment Outcome of 225 Newly Diagnosed Pulmonary Carcinoids: A Single Center Experience of 28 Years
Introduction: Data on pulmonary carcinoids are scarce.
Conference: 15th Annual ENETS conference (2018)
Category: Non digestive NETs (bronchial, thymic, others) - diagnosis and therapy
Presenting Author: M.D. Hong Zhao
Authors: Li Q, Zhou Y, Zhang Y, Chi Y, ...
#640 Chomogranin A, NSE, and 5-Hydroxyindolacetic Acid Measurements in Malignant Carcinoids
Introduction: GEP-NETs are a heterogeneous group of cancers more common in the small intestine which are usually asymptomatic. In patients with malignant carcinoids, a number of tumor markers (TMs) have been considered enclosing urinary 5-hydroxyindolacetic acid (5-HIAA), chromogranin A (CgA), and neuron-specific enolase (NSE) serum levels measurements. Unfortunately, the sensitivity of each TM largely depends on disease extent and the presence of functioning tumors, and thus their usefulness is still unclear.
Conference: 10th Annual ENETS Conference (2013)
Category: Biomarkers
Presenting Author: Professor Franco Lumachi
#65 Deletions of 11q21-q25 are associated with atypical lung carcinoids and a poor clinical outcome
Introduction: Lung carcinoids comprise a group of smoking-unrelated neuroendocrine tumors, which can be classified in typical (TC) and atypical (AC) carcinoids. Classification is complex and its accuracy to predict disease outcome is variable. In a previous array comparative genomic hybridization (arrayCGH) study, we showed that the average number of chromosomal alterations (≥ 1Mb) was significantly higher in ACs than in TCs (512 v. 226 per tumor) and that the most common region of chromosome loss was 11q21-q25 (Neuroendocrinology 2009;90:136-137).
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: MSc Dorian RA Swarts
#462 Genome-Wide Expression Profiling Reveals Downregulation of OTP and CD44 and Upregulation of RET as Indicators of Poor Prognosis in Lung Carcinoids
Introduction: Lung carcinoids comprise a heterogeneous group of neuroendocrine tumors. Only few parameters have been identified that correlated with poor disease outcome, including 11q22-q25 deletions. New biomarkers are required to further improve diagnosis and prediction of prognosis.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: MSc Dorian Swarts
#653 Interobserver Variability of Pulmonary Carcinoids
Introduction: Lung carcinoids are neuroendocrine tumors histopathologically classified into typical (TC; no necrosis, <2 mitoses/2 mm2) and atypical (AC; necrosis or 2-10 mitoses/2 mm2). Identification of mitoses may be hampered by the presence of apoptotic cells, and reported prediction of prognosis based on histopathology varies, especially for ACs.
Conference: 10th Annual ENETS Conference (2013)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: MSc Dorian Swarts
#212 Reduced MEN1 Gene Expression in Pulmonary Carcinoids Is Associated With Metastatic Disease
Introduction: Lung carcinoids are neuroendocrine tumors that can be classified as typical (TC) or atypical (AC) carcinoids. Previously, MEN-1 mutations and associated LOH of 11q13 have been implied in tumorigenesis.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: MSc Dorian R.A. Swarts
#737 Impact of Ki-67 Proliferative Index on Survival in Patients with Typical and Atypical Pulmonary Carcinoids
Introduction: Currently pulmonary carcinoids are separated into typical and atypical tumors based on mitotic count and presence of necrosis, according to the WHO classification. Whereas for GEP NETs the ENETS Guidelines have been incorporated into the WHO classification and grading is based on mitotic counts and Ki-67 index, the use of the Ki-67 index for grading pulmonary carcinoids is still under debate.
Conference: 10th Annual ENETS Conference (2013)
Category: Surgical treatment
Presenting Author: Dr Martina Rudelius
#245 Expression of Somatostatin Receptors and Dopamine 2 Receptor in Lung Carcinoids as a Possible Biotherapy Target
Introduction: Expression of somatostatin receptors (SSTRs) and dopamine 2 receptor (D2R) in neuroendocrine tumors is of clinical importance, as somatostatin analogues and dopamine agonists are used in biotherapy.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Dr Apostolos V. Tsolakis
#360 High Resolution (Epi)genomic Analysis Comparing Pulmonary Carcinoids with a Favorable and a Poor Disease Outcome
Introduction: Lung carcinoids are a heterogenous group of neuroendocrine tumors. MEN1 mutations and 11q22-q25 deletions have been implied in their tumorigenesis. Very few genome wide and methylation studies have been conducted to further elucidate molecular mechanisms underlying tumorigenesis.
Conference:
Category: Basic
Presenting Author: Msc Dorian R.A. Swarts
#406 YF476, a Gastrin Receptor Antagonist, Causes Regression of Tumors and Normalizes Serum Chromogranin A in Patients with Type 1 Gastric Carcinoids
Introduction: Chronic atrophic gastritis (CAG) results in achlorhydria, hypergastrinemia and, in some patients, gastric carcinoids (type 1 GCs). Type 1 GCs may become malignant and metastasize. Current treatments of type 1 GCs, such as polypectomy, somatostatin analogues and antrectomy, have their disadvantages. YF476 – a potent, selective, orally active and well-tolerated gastrin receptor antagonist in pre-clinical studies – prevented, as well as reduced, the number and size of gastric carcinoids and carcinomas in rodent models.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Reidar Fossmark